II. Indications
- Non-Q-Wave Myocardial Infarction
- High risk Unstable Angina
- Percutaneous Coronary Intervention (PCI)
III. Contraindications
- Recent major bleeding
IV. Mechanism
- Fab Antibody fragment
- Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
- Inhibits Fibrinogen binding to Platelets
V. Dosing
-
Percutaneous Coronary Intervention (PCI)
- Load: 0.25 mg/kg IV bolus given 10 to 60 minutes before PCI
- Infuse: 0.125 mcg/kg/min up to 10 mcg/min IV for 12 hours
-
Unstable Angina or non-ST-elevation Myocardial Infarction pending PCI within 24 hours
- Dosing as for PCI, with infusion up to 18 to 24 hours, completing at one hour post-PCI
- Coronary Aneursym in Kawasaki Disease
- Off label use for age >2 months old
- Dosing as used in PCI
VI. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
- Abciximab is excreted in human milk
VII. Resources
- Abciximab (FDA)
- Stoffer (2022) Abciximab, StatPearls, Treasure Island